Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice

Kouji Matsuura, Hideaki Kabuto, Hirofumi Makino, Norio Ogawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.

Original languageEnglish
Pages (from-to)191-194
Number of pages4
JournalNeuroscience Letters
Volume230
Issue number3
DOIs
Publication statusPublished - Jul 25 1997

Fingerprint

Corpus Striatum
Oxidopamine
Cyclosporine
Glucocorticoids
Dopamine
Therapeutics
Theoretical Models
Homovanillic Acid
Injections
Parkinsonian Disorders
Parkinson Disease
Sodium
Acids
Pharmaceutical Preparations

Keywords

  • 6-Hydroxydopamine
  • Combination treatment
  • Glucocorticoid
  • Initial cyclosporin A treatment
  • Monoamine concentration
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice. / Matsuura, Kouji; Kabuto, Hideaki; Makino, Hirofumi; Ogawa, Norio.

In: Neuroscience Letters, Vol. 230, No. 3, 25.07.1997, p. 191-194.

Research output: Contribution to journalArticle

@article{399b1703514840ffb9f03a2dcfb95b53,
title = "Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice",
abstract = "We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.",
keywords = "6-Hydroxydopamine, Combination treatment, Glucocorticoid, Initial cyclosporin A treatment, Monoamine concentration, Parkinson's disease",
author = "Kouji Matsuura and Hideaki Kabuto and Hirofumi Makino and Norio Ogawa",
year = "1997",
month = "7",
day = "25",
doi = "10.1016/S0304-3940(97)00515-6",
language = "English",
volume = "230",
pages = "191--194",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice

AU - Matsuura, Kouji

AU - Kabuto, Hideaki

AU - Makino, Hirofumi

AU - Ogawa, Norio

PY - 1997/7/25

Y1 - 1997/7/25

N2 - We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.

AB - We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.

KW - 6-Hydroxydopamine

KW - Combination treatment

KW - Glucocorticoid

KW - Initial cyclosporin A treatment

KW - Monoamine concentration

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0030748668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030748668&partnerID=8YFLogxK

U2 - 10.1016/S0304-3940(97)00515-6

DO - 10.1016/S0304-3940(97)00515-6

M3 - Article

C2 - 9272693

AN - SCOPUS:0030748668

VL - 230

SP - 191

EP - 194

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 3

ER -